Anidulafungin CAS 166663-25-8

Product Description:

Product Name: Anidulafungin CAS NO: 166663-25-8 

Synonyms:

V-Echinocandin;

VER-002;

Ecalta;

Chemical & Physical Properties:

Appearance: Powder

Assay :≥99.00%

Density: 1.47g/cm3

Boiling Point: 1477℃ at 760mmHg

Flash Point: 847℃

Refractive Index: 1.688

Vapor Pressure: 0mmHg at 25℃

Anidulafungin (brand names: Eraxis (in U.S. and Russia), Ecalta (in Europe)) is a semisynthetic echinocandin used as an antifungal drug. Anidulafungin was originally manufactured and submitted for FDA approval by Vicuron Pharmaceuticals. Pfizer acquired the drug upon its acquisition of Vicuron in the fall of 2005. Pfizer gained approval by the Food and Drug Administration (FDA) on February 21, 2006; it was previously known as LY303366. Preliminary evidence indicates it has a similar safety profile to caspofungin. Anidulafungin has proven efficacy against esophageal candidiasis, but its main use will probably be in invasive Candida infection; it may also have application in treating invasive Aspergillus infection. It is a member of the class of antifungal drugs known as the echinocandins; its mechanism of action is by inhibition of (1→3)-β-D-glucan synthase, an enzyme important to the synthesis of the fungal cell wall.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.